Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 7/20 | 0.60 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.59 |
| ▸ | GHSR | Q92847 | 3/20 | 0.58 |
| ▸ | NPY1R | P25929 | 3/20 | 0.58 |
| ▸ | NPY2R | P49146 | 3/20 | 0.58 |
| ▸ | NPY4R | P50391 | 3/20 | 0.58 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31157965 | 0.96 | UTS2R (0.58) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL31514538 | 0.95 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL29361083 | 0.95 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL30380084 | 0.95 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL29408676 | 0.95 | IL23R (0.65) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL29972966 | 0.94 | IL23R (0.59) | IL23RUTS2RGHSRKISS1R | |
| SCHEMBL31619560 | 0.94 | IL23R (0.59) | IL23RUTS2RGHSRKISS1R | |
| SCHEMBL31619561 | 0.94 | IL23R (0.59) | IL23RUTS2RGHSRKISS1R | |
| SCHEMBL31619568 | 0.94 | UTS2R (0.63) | IL23RUTS2RGHSRNPY1RNPY2R | |
| SCHEMBL31619565 | 0.93 | IL23R (0.58) | IL23RUTS2RGHSRKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120131956-A | Use of growth hormone inhibitors, and pharmaceutical compositions, formulations, and devices containing growth hormone inhibitors | 中山大学中山眼科中心 | 2025-06-13 | — | — | CN | disclosed |
| CN-117545513-A | Precursors and radiotracers for diagnosis of neuroendocrine therapy | 正电子精密股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-115957297-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115957296-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| US-11261215-B2 | Somatostatin prodrugs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261215-B2 | Somatostatin prodrugs | VIP, SSTR4, SSTR5 | IL23R 2061/4885UTS2R 797/4885GHSR 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.